Bendamustine therapy associated resolution of anemia and splenomegaly in myelofibrosis

Am J Hematol. 2016 Feb;91(2):E6-7. doi: 10.1002/ajh.24248.

Authors

Ayalew Tefferi¹, Sonia Cerquozzi¹, Jenny Liaw²

Affiliations

¹ Division of Hematology, Department of Medicine, Mayo Clinic, Rochester, Minnesota.
² Hematologist-Oncologist, Bayside, New York.

PMID: 26587685
DOI: 10.1002/ajh.24248

No abstract available

Publication types

Case Reports
Letter

MeSH terms

Anemia / complications
Anemia / drug therapy*
Antineoplastic Agents, Alkylating / administration & dosage
Antineoplastic Agents, Alkylating / adverse effects
Antineoplastic Agents, Alkylating / therapeutic use*
Bendamustine Hydrochloride / administration & dosage
Bendamustine Hydrochloride / adverse effects
Bendamustine Hydrochloride / therapeutic use*
Humans
Male
Middle Aged
Splenomegaly / complications
Splenomegaly / drug therapy*
Thrombocythemia, Essential / complications
Thrombocythemia, Essential / diagnosis
Thrombocythemia, Essential / drug therapy*
Treatment Outcome

Substances

Antineoplastic Agents, Alkylating
Bendamustine Hydrochloride